Last updated: August 3, 2026
AstraZeneca AB’s Delaware action against Zydus Pharmaceuticals concerned Zydus’s abbreviated new drug application for generic dapagliflozin, the active ingredient in Farxiga. The case was an ANDA patent dispute under the Hatch-Waxman Act, involving AstraZeneca’s patents covering dapagliflozin and its pharmaceutical forms. The litigation created a potential barrier to Zydus’s U.S. launch before the expiration of AstraZeneca’s listed patent rights. [1]
What drug and ANDA were involved in AstraZeneca v. Zydus?
The case involved Farxiga, a prescription sodium-glucose cotransporter-2, or SGLT2, inhibitor marketed by AstraZeneca. Its active ingredient is dapagliflozin propanediol.
| Item |
Details |
| Brand |
Farxiga |
| Active ingredient |
Dapagliflozin propanediol |
| Drug class |
SGLT2 inhibitor |
| Dosage form |
Immediate-release oral tablets |
| Reference sponsor |
AstraZeneca |
| Generic applicant |
Zydus Pharmaceuticals (USA) Inc. |
| Court |
U.S. District Court for the District of Delaware |
| Civil action |
No. 1:18-cv-00664 |
| Statutory basis |
Hatch-Waxman Act, 35 U.S.C. § 271(e)(2) |
| Case type |
ANDA patent-infringement litigation |
Zydus’s ANDA sought approval to market generic dapagliflozin tablets before the expiration of AstraZeneca’s patent rights listed for Farxiga. The filing of a Paragraph IV certification gave AstraZeneca a basis to bring the action before commercial generic launch. [1]
What patents protected Farxiga in the Zydus litigation?
The principal Farxiga patent estate included the original dapagliflozin compound patent and later patents covering crystalline or solid-state forms and therapeutic uses.
U.S. Patent No. 6,515,117
U.S. Patent No. 6,515,117 covered dapagliflozin compounds and related SGLT2-inhibitor technology. The patent had an original expiration date in 2020, subject to any applicable patent-term adjustment or pediatric exclusivity.
The '117 patent was the foundational composition patent for dapagliflozin. Its expiration removed the principal compound-level barrier to generic entry, but later-listed patents could continue to delay approval or expose a generic applicant to infringement claims.
U.S. Patent No. 8,513,202
U.S. Patent No. 8,513,202 covered a crystalline form of dapagliflozin propanediol and related pharmaceutical compositions. The patent had a later expiration date than the original compound patent and represented a formulation and solid-state protection layer for Farxiga.
The '202 patent was commercially significant because a generic applicant could face infringement exposure even after the compound patent expired if its product used the claimed crystalline form or otherwise met the asserted claim limitations.
Method-of-use and later Orange Book patents
AstraZeneca’s broader Farxiga patent estate also included later patents directed to therapeutic uses, combinations, dosing regimens, and additional formulations. The scope of those patents depended on the indication recited in the approved labeling and the claims asserted against the ANDA product.
Method-of-use patents generally create a narrower barrier than composition patents. A generic applicant can sometimes avoid infringement through a section viii statement and a carved-out label, although that strategy depends on the patented indication, FDA labeling, and the factual relationship between the approved use and the generic product.
When did Farxiga lose exclusivity?
Farxiga lost its core small-molecule exclusivity in stages rather than on a single date.
| Exclusivity layer |
Approximate timing |
Commercial effect |
| New chemical entity exclusivity |
2017 |
Prevented ANDA approval during the five-year NCE period |
| Original compound patent |
2020, subject to extensions |
Removed the primary composition-patent barrier |
| Pediatric exclusivity |
Potentially added six months |
Extended listed patent or regulatory protection where applicable |
| Crystalline-form patent |
2026 range |
Maintained a later patent barrier for products practicing the claimed form |
| Later use and combination patents |
2020s |
Created indication-specific or regimen-specific risk |
The precise approval date for a particular generic depends on the patents certified in the ANDA, the outcome or resolution of the litigation, FDA approval timing, any settlement restrictions, and the generic applicant’s ability to avoid infringing claims.
The key commercial point is that the 2020 expiration of the original dapagliflozin compound patent did not necessarily authorize unrestricted generic entry. The later crystalline-form and use patents remained relevant to approval timing and litigation exposure. [2]
What was AstraZeneca’s infringement theory?
AstraZeneca’s complaint alleged that Zydus’s ANDA filing constituted a technical act of infringement under 35 U.S.C. § 271(e)(2). The asserted theory in an ANDA case is based on the product and labeling described in the ANDA, not on an actual commercial sale.
AstraZeneca’s likely infringement theories focused on:
- The active dapagliflozin ingredient.
- The pharmaceutical composition and tablet formulation.
- The crystalline form of dapagliflozin propanediol.
- FDA-approved methods of using dapagliflozin.
- The ANDA product’s proposed labeling and manufacturing specifications.
The case therefore involved both product-by-process questions and claim-scope questions. A generic tablet may avoid an infringement finding if it does not use the claimed solid-state form or if its proposed label excludes the patented method. It may still face infringement liability if the ANDA specifications, manufacturing process, or label establish that the product will practice the asserted claims.
Did Zydus file a Paragraph IV challenge?
Yes. The litigation arose from Zydus’s Paragraph IV certification against AstraZeneca’s listed Farxiga patents.
A Paragraph IV certification states that a listed patent is invalid, unenforceable, or not infringed. It permits the ANDA applicant to challenge the patent before commercial launch. AstraZeneca’s filing of the Delaware action triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), unless the stay was shortened, terminated, or otherwise affected by case resolution.
The Paragraph IV route gave Zydus an opportunity to obtain a judgment that the asserted patents were invalid or not infringed. It also exposed Zydus to a potential injunction and delayed approval if AstraZeneca prevailed.
What was the litigation timeline?
| Date |
Event |
| 2018 |
AstraZeneca filed the Delaware ANDA action against Zydus |
| 2018-2019 |
Pleadings, patent disclosures, claim construction, and discovery proceeded |
| 2019-2020 |
The parties litigated infringement and validity issues concerning Farxiga patents |
| 2020 onward |
The original dapagliflozin compound patent reached its scheduled expiration period |
| Later proceedings |
The docket reflected the parties’ resolution of the ANDA dispute rather than a broad commercial launch ruling on every Farxiga patent |
The case should be distinguished from separate Farxiga actions brought by AstraZeneca against other generic applicants. Results in parallel cases are not automatically binding on Zydus because each ANDA may use different formulations, manufacturing specifications, labels, or certification strategies.
What was the final litigation status?
The action was resolved through a negotiated disposition rather than a publicly reported merits judgment invalidating AstraZeneca’s entire Farxiga patent estate. The public docket reflects termination of the dispute after the parties reached an agreement. [1]
A settlement in an ANDA case does not necessarily establish that the asserted patents are valid or infringed. It generally allocates launch rights and litigation risk between the brand company and generic applicant. The operative settlement terms may determine:
- The earliest permitted Zydus launch date.
- Whether launch is contingent on another generic entrant.
- Whether Zydus receives a license to specified patents.
- Whether the license covers all strengths and indications.
- Whether Zydus can launch an authorized generic or an independent generic.
- Whether the agreement contains supply, manufacturing, or royalty provisions.
Where a settlement agreement is filed under the Federal Trade Commission’s agreements-reporting requirements, the FTC receives the relevant documents for review under the Medicare Prescription Drug, Improvement, and Modernization Act. [3]
Did AstraZeneca and Zydus sign a generic entry settlement?
The case was resolved through a settlement or stipulated dismissal, but the publicly accessible docket does not provide a complete commercial summary of all confidential terms.
The principal business effect of a Farxiga settlement would be to convert uncertain litigation exposure into a defined launch framework. AstraZeneca could preserve some period of branded or licensed exclusivity, while Zydus could obtain a contractual launch date earlier than the latest asserted patent expiration.
A settlement does not eliminate all market-entry risk. The risk can remain if:
- The FDA has not approved the ANDA.
- The product must be modified to avoid a formulation claim.
- A later-listed patent creates a new certification obligation.
- A competing generic launches first.
- The settlement limits only specified indications or strengths.
- The Federal Trade Commission challenges the agreement.
What is the Orange Book status of Farxiga?
Farxiga is a small-molecule drug listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. AstraZeneca’s Orange Book strategy relied on layering patent protection beyond the original dapagliflozin compound patent.
The relevant Orange Book categories included:
| Patent category |
Protection provided |
| Compound patent |
Dapagliflozin molecule and related compounds |
| Solid-state patent |
Crystalline dapagliflozin propanediol form |
| Composition patent |
Tablet or pharmaceutical composition |
| Method-of-use patent |
Use in specified diabetic or cardiovascular populations |
| Combination patent |
Use with other glucose-lowering agents |
Orange Book listing is important because it determines which patents an ANDA applicant must address. It does not, by itself, establish that a patent is valid or infringed. The FDA generally does not adjudicate patent validity or claim scope during ANDA review. [2]
How strong was AstraZeneca’s Farxiga patent estate?
AstraZeneca’s estate was strongest at the composition and solid-state levels and weaker where protection depended on narrow method-of-use limitations.
Strengths
The estate had several commercial advantages:
- The original compound patent protected the active pharmaceutical ingredient broadly.
- The crystalline-form patent extended protection beyond the compound patent.
- The product had multiple approved indications, creating opportunities for method-of-use claims.
- Farxiga’s tablet formulation made solid-state and composition claims commercially relevant.
- The brand had substantial revenue exposure, increasing the value of a negotiated launch date.
Weaknesses
The estate also had vulnerabilities:
- The foundational compound patent was approaching expiration when the case was filed.
- Solid-state patents can face enablement, written-description, anticipation, and obviousness challenges.
- Method-of-use claims can be avoided through label carve-outs.
- ANDA litigation often turns on product-specific specifications that may differ among generic applicants.
- Later patents do not necessarily prevent approval of a product that avoids the claimed form or indication.
Overall, AstraZeneca had a layered estate, but the commercial durability of each layer depended on the exact Zydus product and proposed label.
What generic launch risks existed for Zydus?
Zydus faced four principal launch risks.
Injunction risk
If AstraZeneca prevailed on infringement and the patents were found valid and enforceable, the court could enjoin FDA approval or commercial marketing until patent expiration.
Approval-delay risk
The Paragraph IV lawsuit activated the 30-month stay, delaying final FDA approval unless the litigation was resolved earlier or the stay terminated.
Formulation risk
Zydus needed to ensure that its tablet did not practice the asserted crystalline-form or composition claims. A formulation change could reduce infringement risk but create development, stability, bioequivalence, or approval issues.
Label risk
A carve-out could remove a patented indication from the generic label. That approach can reduce method-of-use exposure but may constrain the commercial product and create induced-infringement disputes if physicians prescribe the product for the carved-out use.
Was biosimilar competition relevant?
No. Dapagliflozin is a chemically synthesized small molecule, not a biologic. The dispute involved an ANDA and Hatch-Waxman patent procedures, not a biosimilar application under the Biologics Price Competition and Innovation Act.
The relevant competitive threats were generic dapagliflozin tablets, combination products, and competing SGLT2 inhibitors such as empagliflozin and canagliflozin.
How did Farxiga compare with competing SGLT2 inhibitors?
| Product |
Active ingredient |
Sponsor |
Regulatory pathway for generics |
Main competitive issue |
| Farxiga |
Dapagliflozin |
AstraZeneca |
ANDA |
Patent and formulation timing |
| Jardiance |
Empagliflozin |
Boehringer Ingelheim/Eli Lilly |
ANDA |
Later patent estate and cardiovascular use |
| Invokana |
Canagliflozin |
Janssen |
ANDA |
Compound, formulation, and method patents |
| Steglatro |
Ertugliflozin |
Merck/Pfizer |
ANDA |
Smaller commercial base |
| Xigduo XR |
Dapagliflozin/metformin |
AstraZeneca |
ANDA |
Combination and extended-release claims |
Farxiga’s patent value depended on the drug’s growing use in type 2 diabetes, heart failure, and chronic kidney disease. Broader clinical adoption increased the revenue at risk from generic entry and raised the value of later method-of-use patents.
What revenue exposure did AstraZeneca face?
Farxiga became one of AstraZeneca’s major growth products. Generic entry threatened both direct Farxiga sales and sales of related dapagliflozin products, including combination products.
Revenue exposure was linked to:
- The timing of generic entry.
- The number of approved generic suppliers.
- The number of strengths launched.
- Whether the generic label included newer cardiovascular or renal indications.
- Payer substitution and formulary control.
- The availability of authorized generic supply.
- The extent to which combination products remained separately protected.
A single generic launch generally produces less price erosion than entry by multiple suppliers. Zydus’s settlement rights, if any, therefore had value beyond the nominal launch date because they could affect the timing and intensity of competition.
Key Takeaways
- AstraZeneca AB v. Zydus, No. 1:18-cv-00664, was a Delaware Hatch-Waxman case involving generic dapagliflozin for Farxiga.
- Zydus challenged AstraZeneca’s listed Farxiga patents through a Paragraph IV certification.
- The key patent layers included the original dapagliflozin compound patent and later crystalline-form and method-of-use protection.
- The compound patent’s expiration did not eliminate all patent barriers to generic entry.
- The case was resolved through a negotiated disposition rather than a reported judgment invalidating AstraZeneca’s full Farxiga estate.
- Biosimilar law was not relevant because dapagliflozin is a small molecule.
- The principal commercial variables were Zydus’s contractual launch date, formulation scope, label carve-outs, FDA approval, and competition from other generic applicants.
FAQs About AstraZeneca v. Zydus Farxiga Litigation
What was Zydus’s product in the AstraZeneca patent case?
Zydus sought approval for generic dapagliflozin tablets, the active ingredient in AstraZeneca’s Farxiga product.
Was AstraZeneca v. Zydus a Paragraph IV case?
Yes. The dispute followed Zydus’s Paragraph IV certification challenging AstraZeneca’s listed Farxiga patents.
Did the case concern a biologic or biosimilar?
No. It concerned a chemically synthesized small molecule regulated through the ANDA pathway.
Can Zydus launch immediately after the original Farxiga compound patent expires?
Not necessarily. Later formulation, crystalline-form, combination, or method-of-use patents may continue to affect approval and launch risk.
Does a settlement prove that AstraZeneca’s Farxiga patents were valid?
No. A settlement allocates litigation and launch risk. It does not constitute a judicial determination that every asserted patent is valid, enforceable, or infringed.
References
-
U.S. District Court for the District of Delaware. (2018). AstraZeneca AB v. Zydus Pharmaceuticals (USA) Inc., No. 1:18-cv-00664, docket record.
-
U.S. Food and Drug Administration. (2024). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).
-
Federal Trade Commission. (2024). Agreements filed under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.
